The microbiota is of interest for the development of a therapeutic strategy against SARS-CoV-2 coronavirus disease 2019 (COVID-19) due to its impact on the host immune system. Proven communications of the gut microbiota with the pulmonary microbiota (gut–lung axis) and the pathway of neural connections between the gut and brain (gut–brain axis) may be important in the face of the pandemic. SARS-CoV-2 was shown to affect almost all organs because of the presence of a host receptor known as angiotensin converting enzyme 2 (ACE2). The ACE2 receptor is mainly present in the brush border of intestinal enterocytes, ciliary cells, and type II alveolar epithelial cells in the lungs. The transport function of ACE2 has been linked to the ecology of gut microbes in the digestive tract, suggesting that COVID-19 may be related to the gut microbiota. The severity of COVID-19 may be associated with a number of comorbidities, such as hypertension, diabetes, obesity, and/or old age; therefore, attention is also paid to multiple morbidities and the modulation of microbiota through comorbidities and medications. This paper reviews the research in the context of the state of the intestinal microbiota and its impact on the cells of the immune system during the SARS-CoV-2 pandemic.
【저자키워드】 COVID-19, SARS-CoV-2, pandemic, microbiota, lungs microbiome, 【초록키워드】 ACE2, obesity, SARS-CoV-2 coronavirus, Comorbidity, ACE2 receptor, diabetes, immune system, medications, hypertension, Brain, cells, severity of COVID-19, Lungs, morbidity, Research, pathway, gut microbiota, disease, therapeutic strategy, microbe, Gut, digestive tract, Transport, connection, modulation, enzyme, host receptor, host immune system, organ, intestinal enterocytes, Affect, Cell, intestinal, shown, alveolar epithelial cell, ciliary, number of comorbidities, the SARS-CoV-2, 【제목키워드】 review, Impact, narrative, System,